Drag a card by its title · ⚙ to size, swap or remove

The company

Incyte Corporation

INCY · Nasdaq

Health CareLife-science toolsJust started moving

INCY stood above a rising 150-day average in 41 of the last 52 weekly readings, including each of the last 20 weeks. It is 3.3% above that average now. Life Science Tools & Research Services: 54% of its 79 stocks in an uptrend (+4 points in four weeks); Health Care: 26% (−10 points in four weeks).

SEC filings

Statistics

Rotation: Just started moving
Weeks in an uptrend: 20 in a row
Industry in uptrend: 54% +4 in 4 wk
Insider buys, 12 months: $0
Insider sales, 12 months: $86.6M
Officials’ trades on record: 7
Institutions holding: 807 (+42)

In the rotation

Each square a week: lit when it closed above a rising 150-day average. 41 of 52 weeks.

20 Apr – 19 Oct

Life-science tools: About half its stocks are in an uptrend and the share has been climbing. Health Care: A minority of its stocks are in an uptrend and the share has fallen sharply over four weeks.

Money in and out

1 Nov 2024 – 1 Oct 2026

Open-market buys above the line and sales below, in dollars.

Congress and officials

7 disclosed lines: House 5, Senate 2, executive 0; 5 people.

Who	Did	Amount	Traded
Robert P. Bresnahan, Jr. House: U.S. House ClerkPA08	sold	$1k–$15k	15 May 2025filed 31 May 2025
Daniel S. Goldman House: U.S. House ClerkNY10	sold	$1k–$15k	6 Mar 2023filed 17 Apr 2023
Gilbert Ray Cisneros, Jr. House: U.S. House ClerkCA39	sold	$1k–$15k	22 Dec 2020filed 11 Jan 2021
Gilbert Ray Cisneros, Jr. House: U.S. House ClerkCA39	bought	$1k–$15k	16 Sep 2020filed 14 Oct 2020
Shelley Moore Capito Senate: U.S. Senate eFDSenator	soldspouse	$1k–$15k	12 Nov 2018filed 8 Dec 2018
Shelley Moore Capito Senate: U.S. Senate eFDSenator	boughtspouse	$1k–$15k	8 Sep 2017filed 6 Oct 2017
Ed Whitfield House: U.S. House ClerkKY01	bought	$1k–$15k	22 Sep 2014filed 8 Oct 2014

Insiders

Buy orders, 12 months0

Sale orders, 12 months35

Buyers · sellers0 · 10

Who	Did	Shares	Traded
Pablo J. CagnoniPresident, Global Head of R&D	sold	2,642at $112.71	15 Oct 2026filed 19 Oct 2026
Pablo J. CagnoniPresident, Global Head of R&D	sold	9,233at $120.50	15 Sep 2026filed 17 Sep 2026
Pablo J. CagnoniPresident, Global Head of R&D	sold	13,985at $120.49	15 Sep 2026filed 17 Sep 2026
Pablo J. CagnoniPresident, Global Head of R&D	sold	10,801at $125.56	19 Aug 2026filed 20 Aug 2026
Pablo J. CagnoniPresident, Global Head of R&D	sold	10,803at $120.04	12 Aug 2026filed 14 Aug 2026
Pablo J. CagnoniPresident, Global Head of R&D	sold	10,640at $122.69	5 Aug 2026filed 7 Aug 2026
Patrick A. MayesEVP & Chief Scientific Officer	sold	2,207at $123.99	5 Aug 2026filed 7 Aug 2026
Patrick A. MayesEVP & Chief Scientific Officer	sold	6,055at $120.43	3 Aug 2026filed 4 Aug 2026
Pablo J. CagnoniPresident, Global Head of R&D	sold	15,888at $119.70	31 Jul 2026filed 4 Aug 2026
Patrick A. MayesEVP & Chief Scientific Officer	sold	14,661at $119.46	31 Jul 2026filed 4 Aug 2026
Patrick A. MayesEVP & Chief Scientific Officer	sold	5,332at $119.42	31 Jul 2026filed 4 Aug 2026
Patrick A. MayesEVP & Chief Scientific Officer	sold	2,187at $119.47	31 Jul 2026filed 4 Aug 2026

Lines filed since 2 January 2026, newest first; every insider’s older lines are on their own page.

Institutions

Holders807+42 on the quarter

New · exited121 · 78

Reported value$22.0B

Quarter to 30 Jun 2026, against 31 Mar 2026; newest filing 31 Aug 2026.

Manager	Shares	Change
BAKER BROS. ADVISORS LPadded · filed 14 Aug 2026	30,762,330$3.5B	+17,918+0.1%
BlackRock, Inc.reduced · filed 7 Aug 2026	18,032,718$2.0B	-945,480−5.0%
Dodge & Coxreduced · filed 13 Aug 2026	11,957,326$1.4B	-295,030−2.4%
VANGUARD CAPITAL MANAGEMENT LLCadded · filed 13 Aug 2026	11,024,289$1.2B	+94,223+0.9%
STATE STREET CORPadded · filed 7 Aug 2026	9,722,336$1.1B	+80,952+0.8%
VANGUARD PORTFOLIO MANAGEMENT LLCadded · filed 13 Aug 2026	7,791,091$883.2M	+31,908+0.4%
AQR CAPITAL MANAGEMENT LLCreduced · filed 14 Aug 2026	5,320,901$603.2M	-487,029−8.4%
GEODE CAPITAL MANAGEMENT, LLCadded · filed 12 Aug 2026	4,750,735$536.5M	+47,551+1.0%
Invesco Ltd.added · filed 14 Aug 2026	4,080,461$462.6M	+209,697+5.4%
WELLINGTON MANAGEMENT GROUP LLPadded · filed 14 Aug 2026	3,575,521$405.3M	+309,385+9.5%

31 Mar 2023 – 30 Jun 2026

News

No headline names it lately.

Everyone who traded it

Pablo J. Cagnoni President, Global Head of R&D · last 15 Oct 20260 · 9

Lee Heeson EVP, Head of Incyte Intl · last 1 Oct 20260 · 1

BAKER BROS. ADVISORS LP Director, 10% owner · last 30 Sep 20261 · 0

Edmund Harrigan Director · last 30 Sep 20260 · 0

Paul J. Clancy Director · last 30 Sep 20260 · 1

David H. Gardner EVP, Chief Strategy Officer · last 22 Sep 20260 · 0

Ramitpal K. Basi EVP, Human Resources · last 25 Aug 20260 · 0

Patrick A. Mayes EVP & Chief Scientific Officer · last 5 Aug 20260 · 5

Michael James Morrissey EVP, Head of Tech. Operations · last 23 Jul 20260 · 3

Mohamed Khairie Issa EVP, Head of U.S. Commercial · last 16 Jul 20260 · 2

Richard A. Hoffman EVP & General Counsel · last 16 Jul 20260 · 0

Steven H. Stein CMO & Head of Late-Stage Dev. · last 16 Jul 20260 · 23

Same industry

OABI OmniAbLeading+67%

TXG 10x GenomicsLeading+59%

AVTR AvantorLeading+45%

ILMN IlluminaLeading+44%

RVTY RevvityLeading+35%

CRL Charles River Laboratories InternationalLeading+34%

MASS 908 DevicesLeading+32%

IQV IQVIA HoldingsLeading+27%

Distance from each stock’s own 150-day average.

Government contracts

No federal award is tied to it.

From its SEC filings

Profit per saleFY 2025 · to 31 Dec 202592.8%

Operating profit marginFY 2025 · to 31 Dec 202529.5%

Return on capital employedFY 2025 · to 31 Dec 202527.8%

Cash conversionFY 2025 · to 31 Dec 2025110%

Research spendFY 2025 · to 31 Dec 202539.9%

Share count trendFY 2025 · to 3 Feb 20260.3%

Cash and equivalentsFY 2025 · to 31 Dec 2025$3.1B

Analyst forecasts

No analyst forecasts yet.